Moreover, comparing GBM patients with CCL21-high expression to CCL21-low expression groups, we found that patients with CCL21-low expression had significantly higher median survival compared to the CCL21-high subset (Log-rank p = 0.0242, Wilcoxon p = 0.0491, Supplemental Figure S1B). The gene discussed is CCL21; the disease is glioblastoma.